***Background.*** Group B Streptococcus (GBS) is a serious cause of meningitis and sepsis in young infants. We assessed maternal immunization with an investigational trivalent GBS polysaccharide-CRM conjugate vaccine, with follow-up of both mothers and infants (clinicaltrials.gov NCT01446289).

***Methods.*** In a phase II, observer-blind, placebo-controlled study, 86 pregnant women were enrolled at 24--35 weeks gestation and randomized 3:2 to receive intramuscular placebo (saline) or trivalent GBS vaccine containing 5 µg of glycoconjugates of each of GBS serotypes Ia, Ib and III. GBS serotype-specific antibodies were measured in mothers pre- and Day 31 post-immunization, and in mothers and infants at delivery and Day 91 post-partum. Safety was assessed up to at least 5 months postpartum.

***Results.*** Of 86 pregnant women enrolled (age 29.8 ± 5.1 years, mean ± SD), 51 received vaccine and 35 placebo at 30.0 ± 3.3 weeks gestation. Low pre-immunization antibodies against serotypes Ia, Ib and III increased 16-, 23- and 20-fold, respectively, at delivery. Among maternal-infant pairs with detectable antibodies, placental transfer was 81% (n = 38), 70% (n = 35) and 65% (n = 33), against serotypes Ia, Ib and III. Infants of vaccinated mothers had increased antibody levels at birth which persisted above placebo group levels through day 91 of age.

                                  ELISA GMCs (µg/mL) \[95% CI\]                                                                                                                                     
  ------------------------------- ------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------
  **Mothers**                     *N*                             *51*                      *35*                      *51*                      *35*                      *51*                      *35*
  **GMC - Delivery** \[95% CI\]   **5.22** \[3.37, 8.1\]          **0.37** \[0.22, 0.63\]   **2.41** \[1.48, 3.94\]   **0.13** \[0.07, 0.23\]   **1.90** \[1.15, 3.12\]   **0.11** \[0.06, 0.19\]   
  **Infants**                     *N*                             *35*                      *25*                      *31*                      *20*                      *30*                      *22*
  **GMC - Birth** \[95% CI\]      **5.14** \[2.64, 10\]           **0.33** \[0.15, 0.71\]   **2.93** \[1.14, 7.57\]   **0.1** \[0.03, 0.32\]    **1.93** \[0.82, 4.59\]   **0.07** \[0.02, 0.18\]   
  **Infants**                     *N*                             *35*                      *25*                      *35*                      *25*                      *35*                      *25*
  **GMC - 91 days** \[95% CI\]    **1.28** \[0.76, 2.16\]         **0.25** \[0.13, 0.46\]   **0.54** \[0.25, 1.19\]   **0.06** \[0.03, 0.16\]   **0.43** \[0.21, 0.86\]   **0.07** \[0.03, 0.15\]   

Mild or moderate solicited reactions were reported in 54% and 53% of vaccine and placebo groups, respectively, with no vaccine-related SAEs reported.

***Conclusion.*** One dose of trivalent GBS vaccine was well-tolerated with no concerning safety signals in pregnant women, and induced increased antibody concentrations in mothers and their infants.
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